Skip to main content
. 2019 May 14;10(35):3302–3311. doi: 10.18632/oncotarget.26906

Figure 2. Proliferation during the course of disease.

Figure 2

a. IB 1 of 20% at initial diagnosis. b. MIB 1 of 50% after 4 years of treatment. c. MIB 1 of 35% at the beginning of treatment with pembrolizumab.